Mycosins Are Required for the Stabilization of the ESX-1 and ESX-5 Type VII Secretion Membrane Complexes

Vincent J. C. van Winden, a Roy Ummels, a Sander R. Piersma, a Connie R. Jiménez, b Konstantin V. Korotkov, c Wilbert Bitter, a,d Edith N. G. Houben d

Department of Medical Microbiology and Infection Control, VU University Medical Center, Amsterdam, The Netherlands; bDepartment of Medical Oncology, OncoProteomics Laboratory, VU University Medical Center, Amsterdam, The Netherlands; dDepartment of Molecular and Cellular Biochemistry, and Center for Structural Biology, University of Kentucky, Lexington, Kentucky, USA; cSection Molecular Microbiology, Amsterdam Institute of Molecules, Medicines and Systems, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands

ABSTRACT Pathogenic mycobacteria contain up to five type VII secretion (T7S) systems, ESX-1 to ESX-5. One of the conserved T7S components is the serine protease mycosin (MycP). Strikingly, whereas MycP is essential for secretion, the protease activity of MycP1 in Mycobacterium tuberculosis has been shown to be dispensable for secretion. The essential role of MycP therefore remains unclear. Here we show that MycP1 and MycP5 of M. marinum have similar phenotypes, confirming that MycP has a second unknown function that is essential for its T7S system. To investigate whether this role is related to proper functioning of the T7S membrane complex, we first analyzed the composition of the ESX-1 membrane complex and showed that this complex consists of EccBCDE1, similarly to what was previously shown for ESX-5. Surprisingly, while mycosins are not an integral part of these purified core complexes, we noticed that the stability of both the ESX-1 complex and the ESX-5 complex is compromised in the absence of their MycP subunit. Additional interaction studies showed that, although mycosins are not part of the central ESX membrane complex, they loosely associate with this complex. We hypothesize that this MycP association with the core membrane complex is crucial for the integrity and functioning of the T7S machinery.

IMPORTANCE Among the major virulence factors of pathogenic mycobacteria are the type VII secretion (T7S) systems. Three of these systems, ESX-1, ESX-3, and ESX-5, have been shown to be crucial for virulence or viability. Here we describe the function of mycosin proteases, which are conserved components within these systems. We show that MycP1 and MycP5 have a second, proteolytic-independent function which is essential for the T7S system. We additionally found that this second essential role is related to the stabilization and proper functioning of their respective ESX membrane core complexes. Finally, we found that this is mediated by a loose association of MycP with the complex. Understanding the essential role of mycosins in type VII secretion systems, which play central roles in the virulence and viability of pathogenic mycobacteria, may provide new intervention strategies to treat tuberculosis.

Received 10 August 2016 Accepted 23 September 2016 Published 18 October 2016

Pathogenic mycobacteria such as Mycobacterium tuberculosis and Mycobacterium leprae remain notorious human pathogens. Important virulence factors of pathogenic mycobacteria are the type VII secretion (T7S) systems and their substrates, which are required for the completion of the macrophage infection cycle and the uptake of nutrients and metabolites across its exceptionally hydrophobic and impermeable cell envelope (CE) (1–4). Pathogenic mycobacteria have up to five of these systems, called ESX-1 to ESX-5, of which ESX-1, ESX-3, and ESX-5 have been shown to be essential for virulence or bacterial viability (1, 5, 6).

ESX-1 is of pivotal importance for the virulence of pathogenic mycobacteria, with ESX-1 substrates being linked to phagosomal escape by destabilizing the phagosomal membrane of macrophages (1, 7). The importance of the ESX-1 system for virulence is also shown by the absence of part of the esx-1 genomic locus in the vaccine strain Mycobacterium bovis BCG (8–10). This deletion is the major determinant for the attenuation of this strain. Also, in the fish pathogen Mycobacterium marinum, a close relative of M. tuberculosis, ESX-1 has been shown to mediate phagosomal escape and deletion of the esx-1 region leads to a strong attenuation in zebrafish (11, 12).

The most recently evolved mycobacterial T7S system, ESX-5, is present only in the cluster of slow-growing mycobacteria. Interestingly, this cluster contains most of the pathogenic species. ESX-5 is responsible for the secretion of many proteins of the so-called proline-glutamic acid (PE) and proline-proline-glutamic acid (PPE) families and is linked to host immune modulation. In addition, ESX-5 has been shown to be essential for in vitro growth of M. marinum and M. bovis BCG by permeating the outer membrane to allow nutrient uptake (4, 13–15).

The ESX systems of mycobacteria share a set of conserved components (16, 17), five of which have one or more predicted transmembrane domains and are cell envelope localized (2). Four of these membrane proteins of the ESX-5 system, i.e., EccB5 to EccE5,
form a large membrane complex of 1.5 MDa (2, 17, 18). Although crystal structures of the soluble domains of the individual components EccB, EccC, and EccD have been published previously (19, 20), there are currently no structural data for this complete membrane complex. Furthermore, the biochemical composition of this complex has been elucidated only for the ESX-5 system, whereas the composition and size of the other ESX complexes remain unknown.

The fifth conserved component with a predicted transmembrane domain is the subtilisin-like protease mycosin (MycP), which is among the most conserved T7S components (21). Although previous pulldown experiments indicated that MycP is not part of the core ESX membrane complex, MycP1 and MycP5 have been shown to be essential for mycobacterial viability and MycP1 and MycP5 are essential for ESX-1- and ESX-5-associated secretion, respectively (4, 22, 23). This indicates that each MycP is essential for and functions specifically within its respective ESX system. The crystal structures of the protease domains of MycP1 and MycP5 show a highly conserved overall subtilisin-like structure, with differences in the substrate binding groove indicating different substrate specificities (24, 25).

Surprisingly, thus far, only one substrate, ESX-1 substrate EspB, is known for any of the mycosins. This protein is processed by MycP1 in vitro and upon secretion by M. tuberculosis (22). Importantly, proteolytic activity of MycP1 is, however, not essential for ESX-1-associated secretion; a catalytically inactive MycP1 mutant of M. tuberculosis even showed increased secretion of ESX-1 substrates (22). Therefore, the essential function of mycosins in secretion remains unknown. The catalytically inactive MycP1 mutant of M. tuberculosis additionally showed decreased virulence in mice, but it is still unknown whether this is a direct effect of the deficiency in EspB processing or due to the observed increased secretion of ESX-1 substrates in this mutant. Together, these observations suggest a dual role of MycP within T7S, with MycP1 being essential for ESX-1 secretion whereas proteolytic activity of MycP1 is not essential for this function.

To further elucidate the dual function of mycosin proteases, we investigated MycP1 and MycP5 functioning in M. marinum. We show that, similarly to the ESX-1 system in M. tuberculosis, ESX-1- and ESX-5-mediated secretion is independent of the (predicted) proteolytic activity of their respective mycosins. However, we show that both the ESX-1 and ESX-5 membrane complexes are not stable in the absence of MycP1 and MycP5, respectively, providing an explanation of why mycosins are essential components in the T7S system.

RESULTS

MycP1 is essential for ESX-1-dependent secretion in M. marinum, while its protease activity is not. To confirm the dual role of MycP1 in another species (22), we first deleted the mycP1 gene of M. marinum via allelic exchange and confirmed that the gene was successfully deleted via PCR analysis (unpublished observation). As expected, this knockout mutant was no longer able to secrete the ESX-1 substrates ExsA, ExsB, and EspB. All examined substrates were still detected in the pellet fractions (Fig. 1A). The ESX-1 substrate EspE was also no longer extractable from intact cells by the mild detergent Genapol X-080 (Fig. 1B), indicating that it was no longer present on the cell surface. ESX-1-dependent secretion was fully complemented by the introduction of the wild-type gene (P1; Fig. 1A and B). To assess the role of the protease activity of MycP1 in secretion, we complemented the ΔmycP1 mutant also with a proteolytically inactive version, mycP1::S354A (P1SA). In agreement with a previous study (22), expression of proteolytic inactive MycP1 resulted in increased secretion of ExsA and ExsB (Fig. 1A). We also observed an increase in the amount of surface-localized EspE (Fig. 1B). Whereas the wild-type strain showed efficient processing of EspB, mainly full-length EspB was detected in the supernatant of the S354A mutant (Fig. 1A), which is consistent with the effect observed for the MycP1 active site mutant of M. tuberculosis (22). There was no increase in the ESX-5-dependent secretion of proteins of the PE subfamily with polymorphic GC-rich repetitive sequences (PE_PGRS), showing that the proteins are not in general more efficiently secreted by the MycP1 proteolytically inactive mutant.

The secretion of ESX-1 substrates has been shown to be essential for contact-dependent lysis of erythrocytes by M. marinum, which serves as a model for the ESX-1-dependent lysis of phagosomal membranes and thus for mycobacterial virulence (11). We confirmed that our wild-type M. marinum strain was capable of lysing erythrocytes, whereas the ΔmycP1 mutant showed no hemolytic activity (Fig. 1D). We could restore this lysing capability by complementing the mutant with both wild-type mycP1 and the proteolytically inactive MycP1 mutant. The latter complementation resulted in significantly increased hemolysis activity compared to that seen with wild-type cells, which is in line with the increased secretion of ESX-1 substrates in this mutant. Together, these data show that, in the presence of a proteolytically inactive MycP1 variant, the ESX-1 system is more active. Finally, we created a version of MycP1, where the access to the active site is partially blocked by placing a bulky amino acid, i.e., a tyrosine, at different positions in the substrate binding groove. We first analyzed the effect of these mutations on the ability of MycP1 of Mycobacterium thermoresistibile (MycP1mth) to cleave its substrate EspB in vitro (25). Introducing a tyrosine at position 239, generating mycP1mth::N239Y, completely blocked protease activity (Fig. 1C). Next, we investigated the effect of the mycP1mth::N239Y mutation (N239Y in M. marinum) on secretion and hemolysis by M. marinum. The bulky mutant (P1Bulky) showed a phenotype similar to that of the active site mutant (Fig. 1A, B, and D), with the bacteria still capable of oversecreting ESX-1 substrates and a more efficient lysing of erythrocytes. This indicates that in addition to protease activity, substrate binding to MycP1 is also not essential for secretion.

MycP5 shows a phenotype similar to that of MycP1. Ates et al. (4) previously showed that a mycP3 transposon mutant in M. marinum is no longer able to secrete the ESX-5 substrate group of PE_PGRS proteins. In this study, we confirmed this secretion defect for an M. marinum mycP5 knockout strain (Fig. 2) and that the original phenotype could be restored by complementation with wild-type mycP5 (P5; Fig. 2). Similarly to the phenotype of MycP3, complementation of the mycP3 knockouot strain with the predicted proteolytically inactive mutant mycP3::S461A (P5SA) or the bulky mutant mycP3::D362Y (P5Bulky) fully restored ESX-5-dependent secretion. However, we did not observe an increase in the secretion of ESX-5 substrates, such as the PE_PGRS proteins or ExsN and LipY. Importantly, LipY, which is normally processed upon secretion (26), was processed in the active site and bulky mutants in a manner similar as seen in the wild-type strain. Also, the pattern seen with the PE_PGRS proteins, which are potentially processed upon secretion, was unaltered. Either MycP5 is not in-
volved in the processing of these substrates or there is redundancy in the protease activities. In conclusion, MycP5 is also essential for protein secretion via ESX-5, but this function is not linked to its putative protease activity.

The composition of the ESX-1 membrane complex is similar to that of the ESX-5 membrane complex. Because MycP is probably an inner membrane protein, we hypothesized that MycP may be involved in the correct functioning of the core membrane complex of T7S systems. We have shown previously by blue native PAGE (BN-PAGE) and antibody (Ab) pulldown experiments that the membrane complex of the ESX-5 system has a size of 1.5 MDa and consists of four conserved membrane proteins, i.e., EccB5, EccC5, EccD5, and EccE5 (2); no MycP5 could be detected in these purified samples. Here, we set out to improve the purification procedure by the introduction of an affinity tag, not only to more accurately detect less-abundant components of the ESX-5 membrane complex but also to determine the composition of the ESX-1 membrane complex.

As the ESX-1 complex had not been analyzed before, we first investigated whether the ESX-1 system of *M. marinum* forms a similar complex. To analyze this, we generated polyclonal antibodies directed against the C-terminal fragment of EccB1. These antibodies were used to identify the ESX-1 membrane complex in *M. marinum* WT strain and various mycP1 mutants. Hemolysis was quantified by determining the OD_{550} absorption of the released hemoglobin. Statistical significant differences between strains were determined with one-way ANOVA; *n* = 6 per strain. *, *P* ≤ 0.05; ***, *P* ≤ 0.001.

**FIG 1** MycP1 is essential for ESX-1-dependent secretion in *M. marinum*, while proteolytic inactive MycP1 shows increased ESX-1 activity. (A) Immunoblot analysis of cell pellets and supernatants of wild-type (WT) *M. marinum* and the mycP1 deletion strain complemented with a WT mycP1 (P1) gene, a mycP1 gene containing an active site mutation (P1SA), and a mycP1 gene with a bulky residue in the substrate pocket (P1Bulk). Proteins were visualized with anti-EsxA, anti-CFP-10, and anti-EspB (ESX-1 substrates). As a control, blots were incubated with antibodies directed against the ESX-5 secreted PE_PGRS proteins and the cytosolic GroEL2 protein. (B) Immunoblot detection of cellular (Genapol Pellet) and surface-localized (Genapol Supernatant) proteins of the *M. marinum* WT strain and various mycP1 mutants. Surface-localized proteins were extracted with Genapol X-080 and stained for the ESX-1 substrate EspE. (C) SDS-PAGE of an in vitro cleavage assay of EspB_{mtub} by WT MycP1_{mtub} (P1), the active site mutant (P1SA), and the bulky mutant (P1Bulk). EspB was visualized by Coomassie brilliant blue (CBB) staining, and MycP1 was analyzed with immunoblotting and stained with anti-His. (D) Hemolysis detection of erythrocytes by the *M. marinum* WT strain and various mycP1 mutants. Hemolysis was quantified by determining the OD_{550} absorption of the released hemoglobin. Statistical significant differences between strains were determined with one-way ANOVA; *n* = 6 per strain. *, *P* ≤ 0.05; ***, *P* ≤ 0.001.
Strep-tag-purified sample. This analysis showed the significantly increased presence of EccB1, EccCa1, EccCb1, EccD1, EccE1, and a hypothetical protein, MMAR_2712 (Table 1), in the samples containing EccCb1-Strep but not in control samples containing purified material from solubilized membranes of wild-type M. marinum. The presence of MMAR_2712 was surprising and might indicate the presence of an additional component. However, homology and structure predictions (Phyre2) indicated that MMAR_2712 is a transmembrane protein with a large periplasmic domain containing a predicted phosphate binding site, an activity unrelated to ESX-1 functioning. Furthermore, the gene encoding this protein is highly conserved in many bacterial species without an ESX-1 system. To test a possible interaction of this protein with the ESX complex, we introduced an N- or a C-terminal hemagglutinin (HA) tag in MMAR_2712 and isolated this protein using HA antibody beads. Subsequently, we used immunoblotting to determine if ESX-1 components were copurified. However, this experiment failed to confirm any interaction of MMAR_2712 with ESX-1 components (unpublished observations). From these combined observations, we conclude that it is unlikely that MMAR_2712 is a component of ESX-1. As with the previously analyzed ESX-5 membrane complex, we were not able to detect significantly more MycP1 peptides in the purified ESX-1 membrane complex, although a few specific MycP1 spectral counts were observed in this analysis. We therefore conclude that the composition and the size of the ESX membrane complex are conserved between the systems.

Next, we also modified the ESX-5 system with a Twin-Strep-tag to allow more-efficient purification of the ESX-5 membrane complex. For this, we complemented the previously characterized M. marinum eccC5 knockout strain (4) with EccC5 containing a C-terminal Twin-Strep-tag. This affinity tag did not interfere with ESX-5-dependent secretion (see Fig. S1 in the supplemental material) or with formation of the 1.5-MDa ESX-5 membrane complex (Fig. 3). The Strep-tag purification of EccC5-Strep was significantly more efficient than the EccCb1-Strep purification and resulted in the copurification of the three known interactors, i.e., EccB5, EccD5, and EccE5, as shown by immunoblot analysis and LC-MS/MS analysis (Table 2). The mass spectrometry analysis revealed that, in this preparation also, there were no additional proteins copurified with EccC5; although spectral counts for MycP5 could be detected, these numbers were not above the spectral count threshold levels (Table 2). We therefore conclude that the mycosins are probably not a stable integral part of the ESX membrane complex.

MycP1 and MycP5 are involved in the stability of the ESX membrane complexes. Although mycosins do not appear to be part of the core complex, the mycosins might still be involved in the correct functioning of this membrane complex. To analyze this, we first analyzed the presence of the ESX-5 membrane complex in the absence or presence of MycP5. While the 1.5-MDa membrane complex was readily visualized on BN-PAGE using polyclonal antibodies directed against EccB5, EccC5, and EccD5 for the wild-type strain, the complex levels were strongly reduced when membrane proteins of the mycP5 knockout mutant were analyzed (Fig. 4A; see also Fig. S2A in the supplemental material).
Complementation with both wild-type mycP3 and mycP2::S461A restored the complex to wild-type levels. This effect on complex formation was not due to decreased stability of the separate subunits, as the expression levels of EccC5 and EccD5 were not affected, whereas EccB5 levels were reduced only slightly upon the mycP2 deletion. A similar effect was observed for the ESX-1 complex; we could detect the 1.5-MDa ESX-1 complex in the wild-type strain, while this complex was not observed in the absence of MycP1 (Fig. 4B). This phenotype could be complemented by introduction of wild-type MycP3 or the active site mutant. Expression levels of EccB5 were not affected by knocking out mycP2. These results suggest that the strongly reduced membrane complex levels in the absence of the respective mycosins were not due to diminished expression of individual membrane components.

The observation that small amounts of the 1.5-MDa ESX-5 membrane complex could be detected in the mycP3 knockout strain suggested that the membrane complex is less efficiently formed or is less stable. To distinguish between these two possibilities, we treated half of the membrane fractions with the cross-linking agent dithiobis(succinimidyl propionate) (DSP) before solubilization was performed to fix protein-protein interactions. DSP cross-linking did not affect ESX-5 complex levels in the wild-type strain. Also, in the negative-control strain, i.e., the eccC5 knockout mutant, the presence of DSP did not restore complex formation of the remaining components. In contrast, cross-linking had a major effect in the mycP3 mutant, as the ESX-5 membrane complex was detectable at wild-type levels in the DSP-treated membranes (Fig. 4C). A similar experiment was performed for ESX-1. Also, in this case DSP treatment of mycP3 knockout membranes resulted in a stabilizing effect on the ESX-1 complex (see Fig. S2B in the supplemental material). This shows that the conserved components of the ESX-1 and ESX-5 membrane complex interact in principle and seem to properly form the ~1.5-MDa membrane complex in the absence of their MycP component but that the complexes more easily dissociate after detergent extraction. We therefore conclude that the mycosins of ESX-1 and ESX-5 are involved in stabilization of the respective membrane complexes. We propose that this stabilization is crucial for membrane complex functioning, explaining the essential role of MycP in the T7S system.

**MycP3 is associated with the ESX-5 core complex.** In the mass spectrometry results from the purified EccB5 and EccC5 protein samples, we did observe a few specific spectral counts for MycP1 and MycP3, respectively. These counts were too low to conclude that MycP is a stable component of the T7S membrane complex. However, we hypothesized that MycP could be loosely associated.

**TABLE 1 Proteins copurified with EccC5,strept**

| Identified protein | Protein description | MW (kDa) | Sequence coverage (%) | MS/MS normalized spectral count | Fold change | P value | NSAF |
|--------------------|---------------------|----------|-----------------------|---------------------------|------------|---------|-------|
| EccC5              | ESX-1 core component| 80.8     | 73.5                  | A 20 B 3 eccC5,strept A 271 B 157 | 19.0       | 2.5 × 10⁻³ | 0.35  |
| EccCh1             | ESX-1 core component| 64.6     | 49.2                  | 7 0 eccC5,strept 172 98 | 37.5       | 2.4 × 10⁻³ | 0.40  |
| EccB1              | ESX-1 core component| 51.3     | 75.5                  | 7 3 eccC5,strept 85 53 | 13.9       | 1.4 × 10⁻³ | 0.37  |
| EccE1              | ESX-1 core component| 50.9     | 64.7                  | 11 1 eccC5,strept 76 46 | 10.1       | 4.6 × 10⁻³ | 0.20  |
| MMAR_2712          | Hypothetical protein| 76.1     | 51.4                  | 9 1 eccC5,strept 70 44 | 11.0       | 3.0 × 10⁻³ | 0.15  |
| EccD3              | ESX-1 core component| 51.3     | 14                    | 0 0 eccC5,strept 18 11 | ∞          | 9.7 × 10⁻⁴ | 0.05  |
| MycP1              | ESX-1 core component| 47.1     | 41.7                  | 0 0 eccC5,strept 11 8   | ∞          | 1.2 × 10⁻³ | 0.03  |

*LC-MS/MS was performed on Strep-tag purified material from M. marinum wild-type (negative control) and M. marinum eccC5,strept cell envelope fractions, followed by a two-way analysis. Proteins that showed >10 normalized spectral counts in both eccC5,strept pull-down samples and a normalized spectral abundance factor (NSAF) of >0.02 were selected. Data in columns A and B represent results from biological replicates. MW, molecular weight.*
with the complex and could thereby stabilize the core complex. To investigate this, we tried to preserve this interaction by testing different mild detergents to solubilize the cell envelope proteins of the mycP5 deletion strain complemented with MycP5 containing a C-terminal HA tag for detection. The HA tag did not interfere with ESX-5-dependent secretion and therefore did not affect MyP5 functioning (see Fig. S1C in the supplemental material). Although several detergents did show solubilization compara-

### TABLE 2 Proteins copurified with EccC5-strep

| Identified protein | Protein description | MW | Sequence coverage (%) | MS/MS normalized spectral count | Fold change | P value | NSAF |
|-------------------|---------------------|----|------------------------|-------------------------------|-------------|---------|------|
| EccC5             | ESX-5 core component | 152.6 | 71.4 | 75 50 706 651 | 10.8 | 5.7 x 10^-6 | 0.42 A B |
| EccE5             | ESX-5 core component | 53.5 | 29.2 | 24 15 118 111 | 5.9 | 4.4 x 10^-3 | 0.20 A B |
| EccB5             | ESX-5 core component | 44.0 | 57.6 | 17 8 103 110 | 8.5 | 4.3 x 10^-3 | 0.21 A B |
| MycP5             | ESX-5 component     | 59.8 | 29.5 | 0 3 9 19 | 6.9 | 4.8 x 10^-3 | 0.15 A B |

*a* LC-MS/MS was performed on Strep-tag-purified material from *M. marinum* wild-type (negative control) and *M. marinum*-ΔeccC5-eccC5-strep cell envelope fractions, followed by a two-way analysis. Proteins that showed >10 normalized spectral counts in both eccC5-strep pulldown samples and a normalized spectral abundance factor (NSAF) of 0.05 were selected. The NSAF was calculated by dividing the normalized spectral counts from the nanoLC-MS/MS experiment by the relative molecular weight (Mr) to obtain the spectral abundance factor (SAF) for each protein. Subsequently, each SAF was normalized by dividing it by the sum of the SAFs of the proteins in the complex. Data in columns A and B represent results from biological replicates. MW, molecular weight.

FIG 4 MycP1 and MycP5 are essential for ESX membrane complex stability. (A) Immunoblot analysis of detergent-solubilized cell envelope fractions of wild-type (WT) *M. marinum* and the mycP5 deletion strain complemented with various mycP5 mutant genes after BN-PAGE (BN) or SDS-PAGE (SDS). Blots were probed with antibodies directed against EccB5 and FtsH. (B) Immunoblot analysis of detergent-solubilized cell envelope fractions of wild-type (WT) *M. marinum* and the mycP1 deletion strain complemented with various mycP1 mutant genes after BN-PAGE (BN) or SDS-PAGE (SDS). Blots were stained with antibodies directed against EccB1 and FtsH. (C) Immunoblot analysis of DSP-cross-linked (+DSP) or DMSO-only-treated (−DSP) detergent-solubilized cell envelope fractions of the *M. marinum* wild-type (WT) strain, an eccC5 deletion strain, and a mycP5 deletion strain after BN-PAGE (BN) or SDS-PAGE (SDS). (D) Immunoblot analysis of solubilized cell envelope fractions (Total) and of proteins copurified with Strep-Tactin-purified MycP5-Strep (P5-Strep). Pulldown experiments using WT *M. marinum* material served as a negative control. (E) Immunoblot analysis of DSP-cross-linked (+DSP) or DMSO-only-treated (−DSP) detergent-solubilized cell envelope fractions of the *M. marinum* mycP5 deletion strain complemented with HA-tagged MycP5 after BN-PAGE (BN). DM, n-decyl-β-D-maltopyranoside; DDM, n-dodecyl-β-D-maltoside; CHAPS, 3-[3-cholamidopropyl]-dimethylammonio]-1-propanesulfonate; MNG-3, maltose neopentyl glycol-3.
ble to that seen with DDM, they did not preserve the interaction of the ESX-5 complex with MycP5 (Fig. 4E). Next, we tried to fix the interaction by treating the cell envelope fractions with DSP prior to the detergent extraction. Interestingly, the DSP treatment resulted in a shift of the HA-tagged MycP5 to a molecular weight corresponding to the ESX-5 core complex, indicating that MycP5 is associated with the ESX-5 complex after cross-linking. To confirm that cross-linking stabilizes the interaction, we performed Strep-Tactin pulldown experiments on cross-linked and detergent-solubilized membrane fractions of either the wild-type strain or a mycP5 deletion strain complemented with MycP5 containing a Twin-Strep-tag at its C terminus. Also, this tag did not interfere with MycP5 functioning (see Fig. S1D). As we observed that DSP severely interfered with the pulldown, we used formaldehyde to fix protein-protein interactions. This cross-linking agent did not affect the pulldown efficiency, as similar MycP5 levels were detected in the elution samples containing the Strep-tagged MycP5, whereas no MycP5 was detected in the elution of the wild-type samples by immunoblotting and Coomassie staining (see Fig. 4D; see also Fig. S3). The purification of MycP5 resulted in the copurification of EccB5 and EccE5, albeit at relatively low levels (Fig. 4D). This interaction could be stabilized by formaldehyde treatment, as we detected higher levels of EccB5 and EccE5 in the cross-linked samples (Fig. 4D). We did not detect the unrelated FtsH membrane component or the abundant GroEL2 cytosolic component in the elution samples (Fig. 4D). We did observe a very-low-intensity signal for EccB5 in the elution fraction; however, in contrast to EccB5 and EccE5, this signal was reduced in the cross-linked elution sample, indicating that this represented nonspecific contamination of the eluate. Our data therefore seem to confirm that MycP5 indeed interacts with the ESX-5 core complex components and that this interaction is essential for the stability and functionality of the ESX complexes corresponding to their respective mycosins.

**DISCUSSION**

In this study, we showed that the active site mutant of MycP1 has a phenotype in *M. marinum* that is similar to that previously observed in *M. tuberculosis* (22). In that previous study, Ohol et al. (22) described a regulatory role of the proteolytic activity of MycP1 in *M. tuberculosis*, with increased secretion by the MycP active site mutation. This mechanism appears to be a conserved feature, as we also observed increased secretion of EsxA, EsxB, and EspE in an *M. marinum* strain harboring a proteolytically inactive MycP1.

We used the ability of *M. marinum* to lyse erythrocytes in an ESX-1-dependent manner, to further analyze ESX-1 functioning. While the *M. marinum ΔmycP1* mutant was indeed unable to lyse erythrocytes, the active site mutant showed significantly increased hemolytic activity, corresponding to the increased activity of the ESX-1 system. It is possible that this was due to the increased secretion of EsxA, as this substrate has been indicated to be responsible for the hemolytic activity (11, 12, 28), although the other substrates of ESX-1 are also secreted in larger amounts. The disparity between the increased membrane lysing capability observed in *M. marinum* and the decreased virulence of *M. tuberculosis* in mice (22) may be explained by the immunogenicity of EsxA, which might result in reduced virulence in later stages of infection (29, 30).

MycP5 showed a phenotype similar to that of MycP1mth::N239Y, with the mutation in the predicted active site not affecting the secretion of ESX-5 substrates. However, we did not observe increased secretion in the mycP5 active site mutant, supporting the suggestion that the observed phenotype of the proteolytically inactive MycP1 is caused by a specific MycP1 substrate, which could be EspB (22). We also did not observe any differences in the (possible) processing of ESX-5 substrates in the mycP5 active site mutant compared to the wild-type *M. marinum* strain. This also means that there are currently no MycP5 substrates known. Therefore, the possibility remains that MycP5 is proteolytically inactive, although it contains all the features known to be essential for protease activity. We prefer the hypothesis that the phenotype of the active site mutant of mycP5 is a result of functional redundancy between MycP3 and other proteases, possibly other mycosins.

We also investigated whether substrate binding is involved in the essential role of mycosins by introducing a bulky amino acid in the substrate binding pocket of MycP1 and MycP5. Because these modifications had an effect similar to that seen with the active site mutations, we can conclude that not only the proteolytic activity of mycosins but also substrate binding is not required for ESX-dependent secretion. It should be mentioned, though, that the mutated residue of MycP1, N239, coordinates the oxyanion hole and, as such, may also affect proteolytic activity. Further experiments are required to determine whether EspB indeed cannot bind to MycP

To study the involvement of mycosin in T7S membrane complex functioning, we isolated both the ESX-1 membrane complex and the ESX-5 membrane complex using a Twin-Strep-tag that was fused at the C terminus of EccC. The Strep-tag purification considerably increased the yield and purity of the purified ESX-5 complex compared to the previous purifications using antibodies (2). Despite the improved purification, we were still unable to detect any additional (less-abundant) components; although a few spectral counts of MycP5 were specifically detected with the EccC5-Strep pulldown, these were not above the spectral count threshold levels. We also were unable to detect specific MycP5 copurification by immunoblot analysis using MycP5 antibodies. Also, in the Strep-pulldown experiments of the ESX-1 complex we could detect a few specific spectral counts for MycP3, but these numbers were again below the threshold level.

We calculated the normalized spectral abundance factor (NSAF) of the Strep-tag-purified complexes using a method similar to a method described before (2) to estimate and compare the relative abundances of individual components of the ESX-1 and ESX-5 complexes. For this, the number of spectral counts (SpC) per isolated protein was divided by the protein's length (L), which was again divided by the result of SpC/L for all isolated proteins in the experiment. This analysis revealed an EccC5/EccB5/EccE5/EccD5 ratio of approximately 2:1:1:1. This ratio is slightly different from the 2:2:1:2 ratio that was found for the antibody pulldown (2). It should be noted that EccC5 might be overrepresented in the Strep pulldown results, as this component contains the affinity tag. The NSAF values of the ESX-1 purified proteins revealed a ratio of 9:7:4:4:1 for EccCa/EccCb/EccBa/EccE1/EccD1, showing a similar distribution, in which the EccC subunits, which are produced as two separate proteins in ESX-1, are present at roughly double the amount seen with the other components. For ESX-1, only EccD3 seemed to be underrepresented compared to ESX-5. This could suggest that the ESX-1 complex is less stable than the
ESX-5 complex, which could also explain the smearing pattern observed in BN-PAGE.

As MycP1 or MycP5 does not appear to be a (stable) component of the ESX-1 or ESX-5 complex in \textit{M. marinum}, it was surprising that the presence of both MycP1 and MycP5 is required for complex stability. The instability of the ESX-5 complex in the \textit{mycP5} knockout was further indicated by the observation that we could not stabilize the ESX-5 complex by cross-linking in the \textit{mycP5} knockout background after repeated freeze-thaw cycles, while this was possible with wild-type samples (unpublished observations). The mechanical stress of this process is apparently already sufficient to dissociate this unstable complex. Using a cross-linking approach, we showed that the ESX-1 complex and already sufficient to dissociate this unstable complex. Using a cross-linking approach, we showed that the ESX-1 complex and ESX-5 complex could be formed in the \textit{mycP5} knockout strains, respectively. Therefore, this indicates that the mycosins are associated with the complexes and are essential for their stability. Furthermore, this stabilization is required for the complex to be functional. The fact that we are unable to detect MycP1 or MycP5 above the threshold levels in the EccC5 and EccC5 pulldown experiments indicates that MycP associates with the membrane complex only loosely and that its interaction is not maintained after detergent extraction. This notion is supported by the observed shift of HA-tagged MycP5 to a molecular weight corresponding to the ESX-5 complex on BN-PAGE, the detection of EccB5 and EccE5 in the elution samples from Strep-Tactin pulldown experiments using Strep-tagged MycP5, and the fact that we observe increased amounts of copurified EccB5 and EccE5 after cross-linking. From this, we conclude that there is indeed an interaction between MycP5 and the ESX-5 core complex, which could explain the observed effects on complex stability. Although we cannot explain the exact mechanism by which a loose association of MycP with the core ESX complex can affect the stability of the complex, there are comparable effects known, as reported in the literature.

In summary, this study for the first time provided insight into the essential function of mycosins in the T7S system. We propose a new model for the T7S systems in mycobacteria, with the mycosins being associated with their respective membrane complexes, which is crucial for the full integrity of the core secretion complex (Fig. 5A). In the absence of mycosin, the complex is less stable and, as a result, nonfunctional (Fig. 5B).

**MATERIALS AND METHODS**

**Bacterial strains and culture conditions.** \textit{M. marinum} \textit{MUSA} (32) was used for all \textit{M. marinum} experiments unless stated otherwise. \textit{M. marinum} wild-type strains and the various derived knockout mutants were grown on 7H10 agar supplemented with 10% Middlebrook oleic acid-albumin-dextrose-catalase (OADC) (BD Biosciences) at 30°C or in Middlebrook 7H9 liquid medium supplemented with 10% Middlebrook ADC and, when required, 0.05% Tween 80 at 30°C and 150 rpm. \textit{Escherichia coli} strains were grown in Luria-Bertani (LB) liquid medium or on LB agar. Medium was supplemented with the appropriate antibiotics at the following concentrations: kanamycin, 25 μg ml⁻¹; hygromycin, 50 μg ml⁻¹; streptomycin, 35 μg ml⁻¹; ampicillin, 100 μg ml⁻¹; chloramphenicol, 30 μg ml⁻¹. \textit{E. coli} strain DH5α was used for DNA cloning and plasmid accumulation and \textit{E. coli} strain Rosetta for recombinant protein expression.

**Generating the \textit{mycP5} knockout in \textit{M. marinum.}** The generation of the \textit{mycP5} and \textit{eccC5} knockout strains that were used in this study was described previously by Ates et al. (4). Notably, a pSMT3 plasmid expressing the outer membrane porin MsP4 was present in these ESX-5 mutants to circumvent the essentiality of this system for growth of \textit{M. marinum}. The \textit{mycP5} knockout mutant did not show a growth defect in the presence of MsP4. A \textit{mycP5} knockout was created in \textit{M. marinum} \textit{MUSA} by allelic exchange using the phAE159 temperature-sensitive phage (33) and a method similar to that described for the creation of the \textit{mycP5} and \textit{eccC5} knockout by Ates et al. (4). The required construct was made by DNA amplification using primers MycP5 LF, MycP5 LR, MycP5 RF, and MycP5 RR (see Table S1 in the supplemental material) and the in-Fusion enzyme. The chromosomal deletion was confirmed by PCR analysis and sequencing. The \textit{M. marinum} \textit{E11 eccC5} transposon mutant that was used in this study has been described previously by Stooop et al. (27).

**Cloning.** The \textit{mycP5} and \textit{mycP5} genes were amplified from \textit{M. marinum} \textit{MUSA} genomic DNA by PCR with anchored primers (EcoRI and

---

**FIG 5** Model of the T7S membrane complex. (A) MycP5 associates with the EccBCDE5 (B/C/D/E) membrane-embedded complex, and, as a result, the T7S ESX-5 complex is stabilized and functional. IM, inner membrane; OM, outer membrane. (B) In the absence of MycP5, the ESX-5 complex is less stable and, as a result, nonfunctional.
HindIII; see Table S1 in the supplemental material). Point mutations, the HA tag, and Twin-Strrep-tag were introduced into mycP5 and mycP6 with nested primers (see Table S1). The generated constructs were additionally cloned as EcoRI-HindIII-digested fragments in pMV361 (34) or with PmII and HindIII in the case of the Twin-Strrep-tag. The C-terminal Twin-Strrep-tag was introduced into EccB5 by modifying the pMV-EccB5 vector described by Ates et al. (4). The vector was digested with Dral- and NsiI linker and containing two annealed oligonucleotides (see Table S1 [OneStrrep-1 and OneStrrep-2]) was subsequently ligated to the digested vector. For the generation of pMV-EccBCab-Twin-Strrep, the eccBCab genes were amplified from M. marinum E11 genomic DNA with two consecutive PCRs. The first PCR amplified eccBCab with an additional 100 to 200 bp on both sides of each gene, and the second PCR amplified eccBCab and introduced a NsiI site in front of the gene (see Table S1). The PCR product was digested with NsiI and ligated into Dral- and NsiI-digested pMV-EccBCab-Twin-Strrep. MycP5mth, MycP5mth S334A, and EspBmth E. coli expression plasmids were previously described by Wagner et al. (25). The mycP5mth-N239Y construct was amplified with anchored primers (Ndel and Xhol) using pET-21d-mycP1mth as a template, and the point mutation was introduced with nested primers (see Table S1). The construct was digested with Ndel and Xhol and ligated to Ndel- and Xhol-digested pet-28a. All plasmids were checked by sequencing of the relevant sections.

Protein secretion and immunoblot analysis. M. marinum strains were grown in 7H9 liquid medium supplemented with ADC, 0.05% Tween 80, and appropriate antibiotics until mid-logarithmic phase, after which the cells were washed and inoculated in 7H9 medium with 0.2% dextrose–0.05% Tween 80 at an optical density at 600 nm (OD600) of 0.4 and grown for another 16 h. The cells (Pellet) were spun down for 10 min at 6,000 × g, washed with phosphate-buffered saline (PBS), and resuspended in SDS loading buffer. Supernatants were passed through 0.45-μm-pore-size filter units, and proteins were precipitated with trichloroacetic acid (TCA) and resuspended in SDS loading buffer. Alternatively, the cells were resuspended in 0.5% Genapol X-080 and incubated for 1 h at room temperature. Samples were spun down and pellets were resuspended in SDS sample loading buffer (Genapol Pellet), while 5× SDS sample buffer was added to the supernatant containing Genapol X-080 (Genapol Supernatant). Proteins were separated on SDS-PAGE gels and transferred to a nitrocellulose membrane, and membranes were stained with anti-GroEL2 (Mtb9.9) (35), anti-CFP-10 (Colo- with anti-GroEL2 (Cs44; John Belisle, NIH, Bethesda, MD, USA), anti- transfected to a nitrocellulose membrane, and membranes were stained with anti-GroEL2, or anti-EccE5 (2) antibodies.

Hemolysis. Mid-log-phase M. marinum bacteria were harvested by centrifugation, washed with PBS, and resuspended in phenol red-free Dulbecco’s modified Eagle’s medium (DMEM) (Gibco). Bacteria from all strains were set to a concentration of 2 OD units ml⁻¹. Defibrinated sheep blood cells (Oxoid) were washed with DMEM and set to a concentration of 8 × 10⁶ cells ml⁻¹. A 75-μl volume of bacteria and 75 μl of erythrocytes were mixed and spun down for 5 min at 610 × g in a round-bottom, 96-well plate. The bacteria and cells were incubated in a 5% carbon dioxide incubator at 32°C for 3 h. The pellets were resuspended and repelted, the supernatant was transferred to a flat-bottom, 96-well plate, and the released hemoglobin was quantified by the measured absorbance at 405 nm. Statistically significant differences between strains were determined with one-way analysis of variance (ANOVA). The sample size consisted of 6 biological replicates per strain, with each biological replicate consisting of 4 technical replicates.

Blue native PAGE analysis of ESX membrane complex formation. M. marinum bacteria were grown to an OD600 of 1 to 1.5 and harvested by centrifugation. Cells were resuspended in PBS–250 mM sucrose and lysed with a One Shot cell disruptor (Constant Systems Ltd.). Unlysed cells were pelleted by centrifugation at 100,000 × g for 30 min and resuspended in PBS–250 mM sucrose. Where stated, samples were cross-linked with DSP or were treated with dimethyl sulfoxide (DMSO) as a negative control and were subsequently quenched with 100 mM glycine–10 mM NaHPO₄ (pH 8.5). Membrane proteins were solubilized for 1 h with 0.25% DDM, the insoluble fraction was removed by centrifugation at 100,000 × g for 20 min, and solubilized proteins (in complexes) were separated on a 3% to 12% NativePage Novex bis-Tris protein gel (Life Technologies). Proteins were transferred to a polyvinylidene difluoride (PVDF) membrane and stained with anti-EccB₁, anti-EccB₅, anti-EccC₅ (2), anti-EccD₅ (2), or anti-HA antibodies.

Isolation of ESX-1 and ESX-5 membrane complexes and MycP5 pulldown. Proteins were solubilized from isolated CE fractions as described above, with the addition of 0.3 mg/ml avidin (Sigma) after the DDM incubation. Solubilized proteins were incubated with Strep-Tactin beads for 30 min in a head-over-head manner, washed with 50 mM HEPES-KOH (pH 7.8)–150 mM KOAc–125 mM sucrose–0.04% DDM, and eluted with 10 mM desthiobiotin, dissolved in the same buffer as was used for the washing. For the MycP5-Strrep-tag purification, where stated, whole cells were treated with 1% formaldehyde and subsequently quenched with 100 mM glycine–10 mM NaHPO₄ (pH 8.5). Proteins were solubilized from isolated CE fractions as described above, and the Strep- Tactin pulldown was performed as described above. SDS solubilization buffer was added to the elution fractions, and samples were heated at 94°C, separated on a 15% SDS-PAGE gel, and visualized by Coomassie staining or transferred to a nitrocellulose membrane and stained with anti-Strep-tag, anti-EccB₁, anti-EccB₅, anti-EccD₅, or anti-EccE₂ (2) antibodies. SDS solubilization buffer was added to the elution fractions, and samples were heated at 94°C, separated on a 12.5% SDS-PAGE gel, and visualized by Coomassie staining or transferred to a nitrocellulose membrane and stained with anti-Strep-tag, anti-EccB₁, anti-EccB₅, anti-EccD₅, or anti-EccE₂ (2) antibodies. LC-MS/MS. Peptides were separated by the use of an UltimateMate 3000 nanoLC-MS/MS system ( Dionex LC-Packings, Amsterdam, the Netherlands) equipped with a 20-cm-by-75-μm-inner-diameter (ID) fused-silica column custom packed with 3-μm-diameter 120-Å reprosil Porous C₁₈ aq (Dr. Maisch GmbH, Ammerbuch-Entringen, Germany). After injection, peptides were trapped at 6 μl/min on a 10-mm-by-100-μm-ID trap column packed with 5 μm 120-Å reprosil Porous C₁₈ aq using 2% buffer B (buffer A, 0.5% acetic acid–Milli-Q Water [MQ]; buffer B, 80% acetonitrile [ACN]–0.5% acetic acid–MQ) and separated at 300 nl/min in a 10% to 40% buffer B gradient in 60 min (90 min, injection to injection). Eluting peptides were ionized at a potential of +2 kV into a Q Exactive mass spectrometer (Thermo, Fisher, Bremen, Germany). Intact masses were measured at a resolution of 70,000 (at m/z 200) in the Or-
An open-source software tool (ATCC BAA-535M) FASTA file (5,418 entries) using MaxQuant 1.4.1.2 (37). Enzyme specificity was set to trypsin, and up to two missed cleavages were allowed. Cysteine carboxamidomethylation (Cys; +57.021464 Da) was treated as a fixed modification and methionine oxidation (Met, +15.994915 Da) and N-terminal acetylation (N terminal, +42.010565 Da) as variable modifications. Peptide precursor ions were searched with a maximum mass deviation of 6.0 ppm and fragment ions with a maximum mass deviation of 20 ppm (default MaxQuant settings). Peptide and protein identifications were filtered at a false-discovery rate (FDR) of 1% using the decoy database strategy. Proteins that could not be differentiated based on MS/MS spectra alone were grouped into protein groups (default MaxQuant settings).

Proteins were quantified (in a label-free manner) by spectral counting, i.e., by determining the sum of all MS/MS spectra for each identified protein (38). For quantitative analysis across samples, spectral counts for identified proteins in a sample were normalized to the sum of spectral counts for that sample. This gives the spectral count contribution of a protein relative to the contribution of all spectral counts in the sample. For comparisons of different biological samples, these normalized spectral counts were used to calculate ratios. In this way, we were able to correct for loading differences between samples. Differential analysis of samples was performed using the beta-binomial test (39), which takes into account within- and between-sample variations, giving fold change values and associated P-values for all identified proteins. Protein cluster analysis of the differentially expressed proteins was performed using hierarchical clustering in R. The protein abundances were normalized to zero mean and unit variance for each individual protein. Subsequently, the Euclidean distance measure was used for protein clustering.

**Accession number(s).** The mass spectrometry proteomics data has been deposited in the ProteomeXchange Consortium via the PRIDE (40) partner repository with the data set identifier PXD003766.

**SUPPLEMENTAL MATERIAL**

Supplemental material for this article may be found at [lookup/suppl/doi:10.1128/mBio.01471-16/-/DCSupplemental](https://doi.org/10.1128/mBio.01471-16/-/DCSupplemental).

**Figure S1**, TIF file, 1.9 MB.
**Figure S2**, TIF file, 0.8 MB.
**Figure S3**, TIF file, 0.2 MB.
**Table S1**, DOCX file, 0.01 MB.

**ACKNOWLEDGMENTS**

We thank Louis Ates and Eveline Weerdenburg for help with the hemo-
lysis assays, Florence Pojer of the Stewart Cole laboratory in Lausanne, Switzerland, for supplying us with polyclonal rat anti-EspB antibodies, and Joen Luirink for helpful discussions.

This work was funded by a VIDI grant from the Netherlands Organiza-
tion of Scientific Research (NWO) (E.N.G.H.) and by the CCA from the VU University Medical Center.

**FUNDING INFORMATION**

This work, including the efforts of Konstantin Korotkov, was funded by HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) (R01AI19022).

This work was funded by a VIDI grant from the Netherlands Organization of Scientific Research (NWO) and by the CCA from the VU University Medical Center.

**REFERENCES**

1. Stanley RA, Raghavan S, Hwang WW, Cox JS. 2003. Acute infection and macrophage subversion by Mycobacterium tuberculosis require a specialized secretion system. Proc Natl Acad Sci U S A 100:13001–13006. [http://dx.doi.org/10.1073/pnas.2235593100](http://dx.doi.org/10.1073/pnas.2235593100).
2. Houwen EN, Bestebroer J, Ummels R, Wilson L, Piersma SR, Jiménez CR, Ottenhoff TH, Luirink J, Bitter W. 2012. Composition of the type VII secretion system membrane complex. Mol Microbiol 86:472–484. [http://dx.doi.org/10.1111/j.1365-2958.2012.06206.x](http://dx.doi.org/10.1111/j.1365-2958.2012.06206.x).
3. Siegrist MS, Unnikrishnan M, McConnell MJ, Biewalsky M, Cheng T-Y, Siddiqui N, Fortune SM, Moody DB, Rubin EJ. 2009. Mycobacterial ESX-3 is required for mycobactin-mediated iron acquisition. Proc Natl Acad Sci U S A 106:18792–18797. [http://dx.doi.org/10.1073/pnas.0900589106](http://dx.doi.org/10.1073/pnas.0900589106).
4. Ates LS, Ummels R, Commandeur S, van de Weerd R, van der Weerd R, Sparrius M, Weerdenburg E, Alber M, Kalscheuer R, Piersma SR, Abdallah AM, Abd El Ghany M, Abdel-Haleem AM, Pain AM, Jiménez CR, Bitter W, Houwen EN. 2015. Essential role of the ESX-5 secretion system in outer membrane permeability of pathogenic mycobacteria. PLOS Genet 11:e1005190. [http://dx.doi.org/10.1371/journal.pgen.1005190](http://dx.doi.org/10.1371/journal.pgen.1005190).
5. Abdallah AM, Gey Van Pittius NC, Champion PA, Cox J, Luirink J, Vandenbroucke-Grauls CMJE, Appelmelk BJ, Bitter W. 2007. Type VII secretion—mycobacteria show the way. Nat Rev Microbiol 5:883–891.
6. Stoop EJ, Bitter W, van der Sar AM. 2012. Tubercle bacilli rely on a type VII army for pathogenicity. Trends Microbiol 20:477–484. [http://dx.doi.org/10.1016/j.tim.2012.07.001](http://dx.doi.org/10.1016/j.tim.2012.07.001).
7. Houwen B, Demangel C, van Ingen J, Perez J, Baldeón L, Abdallah AM, Caleuchlern L, Bottai D, van Zon M, de Punder K, van der Laan T, Kant A, Bossers-de Vries R, Willemsen P, Bitter W, van Soolingen D, Brosch R, van der Wel N, Peters PJ. 2012. ESX-1-mediated translocation to the cytosol controls virulence of mycobacteria. Cell Microbiol 14:1287–1298. [http://dx.doi.org/10.1111/j.1462-5822.2012.01799.x](http://dx.doi.org/10.1111/j.1462-5822.2012.01799.x).
8. Philipp WJ, Nair S, Guglielmi M, Lagranderie M, Gicquel B, Cole ST. 1996. Physical mapping of Mycobacterium bovis BCG Pasteur reveals secretions from the genome map of Mycobacterium tuberculosis H37Rv and from M. bovis. Microbiology 142:3135–3145. [http://dx.doi.org/10.1099/13500872-142-11-3135](http://dx.doi.org/10.1099/13500872-142-11-3135).
9. Gordon SV, Brosch R, Billaut A, Garnier T, Eglemeier K, Cole ST. 1999. Identification of variable regions in the genomes of tubercle bacilli using bacterial artificial chromosome arrays. Mol Microbiol 32:643–655. [http://dx.doi.org/10.1046/j.1365-2958.1999.01383.x](http://dx.doi.org/10.1046/j.1365-2958.1999.01383.x).
10. Hsu T, Hingley-Wilson SM, Chen B, Chen M, Dai AZ, Morisaki H, Engel JN, Brown EJ. 2004. Mycobacterial virulence gene cluster extending RD1 is required for cytolsis, bacterial spreading and ESAT-6 secretion. Mol Microbiol 53:1677–1693. [http://dx.doi.org/10.1111/j.1365-2958.2004.04261.x](http://dx.doi.org/10.1111/j.1365-2958.2004.04261.x).
11. Smith J, Manoranjan J, Pan M, Xu J, Liu J, Mcdonald KL, Laronde-Leblanc N, Gao L, Bohsali A, Szyk A, Brown EJ. 2008. Evidence for pore formation in host cell membranes by ESX-1-secreted ESAT-6 and its role in Mycobacterium marinum escape from the vacuole. Infect Immun 76:5478–5487.
12. Abdallah AM, Verboom T, Weerdenburg EM, Gey Van Pittius NG, Mahasha PW, Jiménez C, Parra M, Cadieux N, Brennan MJ, Appelmelk BJ, Bitter W. 2009. PPE and PE-PGRS proteins of Mycobacterium marinum are transported via the type VII secretion system ESX-5. Mol Microbiol 73:329–340. [http://dx.doi.org/10.1111/j.1365-2958.2009.06783.x](http://dx.doi.org/10.1111/j.1365-2958.2009.06783.x).
14. Abdallah AM, Bestebroer J, Savage ND, de Punder K, van Zom M, Wilson L, Korbee CJ, van der Sar AM, Ottenhoff TH, van der Wel NN, Bitter W, Peters PJ. 2011. Mycobacterial secretion systems ESX-1 and ESX-5 play distinct roles in host cell death and inflammasome activation. J Immunol 187:4744–4753. http://dx.doi.org/10.4049/jimmunol.1101457.

15. Bottai D, di Luca M, Majlessi L, Frigui W, Simeone R, Sayes F, Bitter W, Brennan MJ, Leclerc C, Batoni G, Campa M, Brosch R, Esin S. 2012. Disruption of the ESX-5 system of Mycobacterium tuberculosis causes loss of PPE protein secretion, reduction of cell wall integrity and strong attenuation. Mol Microbiol 83:1195–1209. http://dx.doi.org/10.1111/j.1365-2958.2012.08001.x.

16. Gey Van Pittius NC, Gamilienid J, Hide W, Brown GD, Siezen RJ, Bayers AD. 2001. The ESAT-6 gene cluster of Mycobacterium tuberculosis and other high G+C Gram-positive bacteria. Genome Biol 2: http://dx.doi.org/10.1186/gb-2001-2-10-research0044.

17. Bitter W, Houben ENG, Bottai D, Brodin P, Brown EJ, Cox JS, Derbyshire K, Fortune SM, Gao L, Liu J, Gey van Pittius NC, Pym AS, Rubin EJ, Sherman DR, Cole ST, Brosch R. 2009. Systematic genetic nomenclature for type VII secretion systems. PLoS Pathog 5:e1000507. http://dx.doi.org/10.1371/journal.ppat.1000507.

18. Guinn KM, Hickey MJ, Mathur SK, Zaken KL, Grotzke JE, Lewinsohn DM, Smith S, Sherman DR. 2004. Individual RD1 -region genes are required for export of ESAT-6/CFP-10 and for virulence of Mycobacterium tuberculosis. Mol Microbiol 51:539–570. http://dx.doi.org/10.1046/j.1365-2958.2003.03844.x.

19. Rosenberg OS, Dovala D, Li X, Connolly L, Bendebury A, Finer-Moore RJ, Prehna G, Overall CM, Strynadka NC. 2011. Mycobacterial secretion systems ESX-1 and ESX-5 play distinct roles in host cell death and inflammasome activation during mycobacterial infection. Cell Microbiol 10:1866–1878. http://dx.doi.org/10.1111/j.1462-5822.2008.01177.x.

20. Brandt I, Elhay M, Rosenkranz I, Lindblad EB, Andersen P. 2000. ESAT-6 subunit vaccination against Mycobacterium tuberculosis. Infect Immun 68:791–795. http://dx.doi.org/10.1128/IAI.68.2.791-795.2000.

21. Dietrich J, Andersen C, Rappuoli R, Doherty TM, Jensen CG, Andersen VC, Munksgaard M, Maxted RJ, Vizcaíno J, Deutsch E, Wang R. 2004. Type IV pilus biogenesis in Neisseria meningitidis: PIPW is involved in a step occurring after pilus assembly, essential for fibre stability and function. Mol Microbiol 55:55–64. http://dx.doi.org/10.1111/j.1365-2958.2004.04364.x.

22. Abdallah AM, Verboom T, Hennes F, Søf, M, Strong M, Eisenberg D, Musters RJ, Vandenbroucke-Grauls CM, Appelmelk BJ, Luijking J, Bitter W. 2006. A specific secretion system mediates PPE41 transport in pathogenic mycobacteria. Mol Microbiol 62:667–679. http://dx.doi.org/10.1111/j.1365-2958.2006.05409.x.

23. Jain P, Hsu T, Arai M, Biermann K, Thaler DS, Nguyen A, González T, Bocciello JM, Krizskis J, Chen B, Larsen MH, Jacobs WR, Jr. 2014. Specialized transcription designed for precise high-throughput unmarked deletions in Mycobacterium tuberculosis. mBio 5:0e1245-14. http://dx.doi.org/10.1128/mBio.01245-14.

24. Stover CK, de la Cruz VF, Fuerst TR, Burlein JE, Benson LA, Bennett LT, Belsal GP, Young JF, Lee MH, Haflut GF, Snapper SB, Barletta RG, Jacobs WR, Jr, Bloom BR. 1991. New use of BCG for recombinant proteins. Mol Microbiol 5:155–165. http://dx.doi.org/10.1111/j.1365-2958.1991.tb04805.x.

25. alderson MR, Bement T, Day CH, Zhu L, Moleish D, Skiey YA, Coler R, Lewinsohn DM, Reed SG, Dillon DC. 2000. Expression cloning of an immunodominant family of Mycobacterium tuberculosis antigens using human CD4(+ ) T cells. J Exp Med 191:551–560. http://dx.doi.org/10.1084/jem.191.3.551.

26. Van Bloois E, Dekker HL, Fröderberg L, Houben EN, Urbanus ML, de Koster CG, de Gier JW, Luijking J. 2008. Detection of cross-links between PsH, YidC, HIK/C suggests a linked role for these proteins in quality control upon insertion of bacterial inner membrane proteins. FEMS Lett 582:1419–1424. http://dx.doi.org/10.1016/j.fleu.2008.02.082.

27. Cox J, Mann M. 2008. MaxQuant enables high peptide identification rates, individualized P.P.B.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol 26:1367–1372. http://dx.doi.org/10.1038/nbt.1511.

28. Liu H, Sadygov RG, Yates JR. 2004. A model for random sampling and estimation of relative protein abundance in shotgun proteomics. Anal Chem 76:1419–2003. http://dx.doi.org/10.1021/ac0498563.

29. Pham TV, Piersma SR, Warmoes M, Jimenez CR. 2010. On the beta-binomial model for analysis of spectral count data in label-free tandem mass spectrometry-based proteomics. Bioinformatics 26:363–369. http://dx.doi.org/10.1093/bioinformatics/btp677.